World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials

M. Boers*, P. Tugwell, D. T. Felson, P. L.C.M. Van Riel, J. R. Kirwan, J. S. Smolen, N. Khaltaev

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

281 Citations (Scopus)

Abstract

The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.

Original languageEnglish
Pages (from-to)86-89
Number of pages4
JournalJournal of Rheumatology
Volume21
Issue numberSUPPL. 41
Publication statusPublished - 15 Sep 1994

Keywords

  • Clinical trials
  • Endpoints
  • RA

Fingerprint Dive into the research topics of 'World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials'. Together they form a unique fingerprint.

Cite this